Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 28 May 2021, including: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Five Late-Breakers To Watch For At ASCO 2021" - Scrip, 20 May, 2021.)
(Also see "More Small Biotechs Are Launching Drugs On Their Own" - Scrip, 20 May, 2021.)
(Also see "Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line" - Scrip, 24 May, 2021.)
(Also see "Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel" - Scrip, 21 May, 2021.)
(Also see "Novo Nordisk's Keenly Awaited Semaglutide Trial To ‘Redefine’ Alzheimer’s?" - Scrip, 25 May, 2021.)